SRS Capital Advisors Inc. Has $1.78 Million Position in Zoetis Inc. (NYSE:ZTS)

SRS Capital Advisors Inc. lifted its stake in shares of Zoetis Inc. (NYSE:ZTS) by 49.5% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 10,913 shares of the company’s stock after buying an additional 3,611 shares during the quarter. SRS Capital Advisors Inc.’s holdings in Zoetis were worth $1,778,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Callahan Advisors LLC lifted its stake in shares of Zoetis by 90.4% during the 4th quarter. Callahan Advisors LLC now owns 13,105 shares of the company’s stock worth $2,135,000 after buying an additional 6,221 shares during the last quarter. Pensionfund Sabic lifted its stake in shares of Zoetis by 55.6% during the 4th quarter. Pensionfund Sabic now owns 11,200 shares of the company’s stock worth $1,825,000 after buying an additional 4,000 shares during the last quarter. PFW Advisors LLC acquired a new stake in shares of Zoetis during the 4th quarter worth about $1,764,000. CIBC Asset Management Inc lifted its stake in shares of Zoetis by 24.1% during the 4th quarter. CIBC Asset Management Inc now owns 237,369 shares of the company’s stock worth $38,617,000 after buying an additional 46,050 shares during the last quarter. Finally, Alberta Investment Management Corp lifted its stake in shares of Zoetis by 2,050.0% during the 4th quarter. Alberta Investment Management Corp now owns 30,100 shares of the company’s stock worth $4,904,000 after buying an additional 28,700 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Price Performance

ZTS stock opened at $167.58 on Friday. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. Zoetis Inc. has a 12 month low of $144.80 and a 12 month high of $200.53. The firm has a market cap of $75.04 billion, a P/E ratio of 30.64, a P/E/G ratio of 2.78 and a beta of 0.90. The company’s 50-day moving average price is $166.30 and its two-hundred day moving average price is $177.30.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, February 13th. The company reported $1.40 EPS for the quarter, beating the consensus estimate of $1.37 by $0.03. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The firm had revenue of $2.32 billion for the quarter, compared to analyst estimates of $2.30 billion. On average, analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be issued a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a dividend yield of 1.19%. The ex-dividend date is Monday, April 21st. Zoetis’s dividend payout ratio (DPR) is presently 36.56%.

Insider Activity at Zoetis

In related news, EVP Roxanne Lagano sold 326 shares of Zoetis stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total transaction of $55,804.68. Following the sale, the executive vice president now directly owns 16,107 shares of the company’s stock, valued at approximately $2,757,196.26. The trade was a 1.98 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.16% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. StockNews.com cut shares of Zoetis from a “buy” rating to a “hold” rating in a research note on Tuesday, February 25th. UBS Group started coverage on shares of Zoetis in a research note on Monday, December 9th. They issued a “neutral” rating and a $196.00 price objective for the company. Piper Sandler lifted their price objective on shares of Zoetis from $200.00 to $205.00 and gave the stock an “overweight” rating in a research note on Thursday. Stifel Nicolaus dropped their price objective on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. Finally, Leerink Partnrs upgraded shares of Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. Two equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $215.90.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.